Junzheng Wu

Junzheng Wu

Auto-generated profile, based on publicly available information

Junzheng Wu

Chengdu Rongsheng Pharmaceuticals Co., Ltd, Chengdu, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLCesheng Li
Cesheng Li
DYDing Yu
Ding Yu
XWXiao Wu
Xiao Wu
HLHong Liang
Hong Liang
ZZZhijun Zhou
Zhijun Zhou
Xiaoming YangXiaoming Yang
Xiaoming Yang
To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 35.7% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.

9 December 2022 in Cell Discovery
Verified
Journal Article
Open access
PDF file
HLHong Liang
Hong Liang
XNXuanxuan Nian
Xuanxuan Nian
JWJunzheng Wu
Junzheng Wu
DLDong Liu
Dong Liu
LFLu Feng
Lu Feng
Xiaoming YangXiaoming Yang
Xiaoming Yang
The immunity of patients who recover from coronavirus disease 2019 (COVID-19) could be long lasting but persist at a lower level. Thus, recovered patients still need to be vaccinated to prevent reinfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or its mutated variants. Here, we report that the inactivated COVID-19 vaccine can stimulate immunity in recovered patients to maintain high levels of anti-receptor-binding domain (RBD) and anti-nucleocapsid protein (NP) antibody titers within 9 months, and high neutralizing activity against the prototype, Delta, and Omicron strains was observed. Nevertheless, the antibody response decreased over time, and the Omicron variant exhibited more pronounced resistance to neutralization than the prototype and Delta strains. Moreover, the intensity of the SARS-CoV-2-specific CD4+ T cell response was also increased in recovered patients who received COVID-19 vaccines. Overall, the repeated antigen exposure provided by inactivated COVID-19 vaccination greatly boosted both the potency and breadth of the humoral and cellular immune responses against SARS-CoV-2, effectively protecting recovered individuals from reinfection by circulating SARS-CoV-2 and its variants.

5 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLCesheng Li
Cesheng Li
DYDing Yu
Ding Yu
XWXiao Wu
Xiao Wu
HLHong Liang
Hong Liang
ZZZhijun Zhou
Zhijun Zhou
Xiaoming YangXiaoming Yang
Xiaoming Yang

5 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
CLCesheng Li
Cesheng Li
DYDing Yu
Ding Yu
XWXiao Wu
Xiao Wu
HLHong Liang
Hong Liang
ZZZhijun Zhou
Zhijun Zhou
Xiaoming YangXiaoming Yang
Xiaoming Yang
To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 64.3% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.

15 November 2023 in Medcomm
Verified
Journal Article
Open access
JWJunzheng Wu
Junzheng Wu
HYHuichuan Yang
Huichuan Yang
DYDing Yu
Ding Yu
Xiaoming YangXiaoming Yang
Xiaoming Yang
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is capable of large‐scale transmission and has caused the coronavirus disease 2019 (COVID‐19) pandemic. Patients with COVID‐19 may experience persistent long‐term health issues, known as long COVID. Both acute SARS‐CoV‐2 infection and long COVID have resulted in persistent negative impacts on global public health. The effective application and development of blood‐derived products are important strategies to combat the serious damage caused by COVID‐19. Since the emergence of COVID‐19, various blood‐derived products that target or do not target SARS‐CoV‐2 have been investigated for therapeutic applications. SARS‐CoV‐2‐targeting blood‐derived products, including COVID‐19 convalescent plasma, COVID‐19 hyperimmune globulin, and recombinant anti‐SARS‐CoV‐2 neutralizing immunoglobulin G, are virus‐targeting and can provide immediate control of viral infection in the short term. Non‐SARS‐CoV‐2‐targeting blood‐derived products, including intravenous immunoglobulin and human serum albumin exhibit anti‐inflammatory, immunomodulatory, antioxidant, and anticoagulatory properties. Rational use of these products can be beneficial to patients with SARS‐CoV‐2 infection or long COVID. With evidence accumulated since the pandemic began, we here summarize the progress of blood‐derived product therapies for COVID‐19, discuss the effective methods and scenarios regarding these therapies, and provide guidance and suggestions for clinical treatment.

5 December 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JWJunzheng Wu
Junzheng Wu
HZHang Zhang
Hang Zhang
TLTong Lian
Tong Lian
YDYaling Ding
Yaling Ding
CSChunlei Song
Chunlei Song
HLHong Liang
Hong Liang